Army Medical Research Institute of Infectious Diseases

Latest stories

  • in Healthcare IT, News

    CSRA Subsidary’s Plague Vaccine Receives FDA Orphan Drug Designation

    A plague vaccine being developed by a CSRA subsidiary has received orphan drug status from the U.S. Food and Drug Administration as a treatment for pre-exposure prophlaxis of Yersinia pestis infection. CSRA said Wednesday its DynPort Vaccine Company works with the Defense Department on the development of the recombinant rF1V plague vaccine that will be added to the DoD’s medical countermeasures portfolio […] More

  • in News, Products & Service

    Army Tests Ebola Vaccine Candidate With Yisheng Biopharma’s PIKA Adjuvant in Mice

    The U.S. Army has begun preclinical trials of its vaccine candidate against Ebola virus in combination with the PIKA adjuvant platform developed by China-based Yisheng Biopharma. Study results show that mice that received a combination of the Army Medical Research Institute of Infectious Diseases’ virus-like particle-based vaccine and Yisheng’s PIKA adjuvant platform demonstrated 100 percent […] More

  • in News, Products & Service

    Army Taps 4 Companies for $25M Medical Research Support Contract

    The U.S. Army has selected four companies to provide laboratory research animals and devices to the Army Medical Research Institute of Infectious Diseases and other Defense Department agencies under a $25 million contract. DoD said Wednesday the firm-fixed-price contract covers support for basic research through July 12, 2020. The following companies may receive blanket purchase agreements within […] More